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Dear Editor,
The identification of prognostic models for overall
survival (OS) of relapsed/refractory (R/R) chronic lym-
phocytic leukemia (CLL) treated with novel target drugs,
such as B-cell receptor (BCR) and BCL-2 inhibitors,
represents an unmet clinical need. Recently, our group
proposed a survival-risk score for real-life R/R CLL
patients treated with Ibrutinib (SRSI).
1 This SRSI is based
on three laboratory parameters, β2 microglubulin (β2 M,
1 point for cases with β2 M > 5mg/L), lactic dehy-
drogenase values (LDH, 2 points for cases with LDH >
upper limit of normal), and hemoglobin level (2 points for
men with hemoglobin < 11 g/L and 2 points for women
with hemoglobin < 12 g/L) (Supplementary Table 1), and
represents a powerful and easily applicable prognostic
tool for the prediction of OS. Indeed, unique information
originated from a real-life retrospective study with a huge
number of R/R CLL patients treated either with che-
moimmunotherapy or with new drugs, and proposed a
comprehensive risk score for the OS prediction. On the
other hand, the randomized trial comparing Idela-R ver-
sus R showed the greater performance of the Idela-R in all
experimental settings [i.e., IGHV-unmutated cases, del
(17p) cases] (2). Moreover, the final results of the same
randomized trial (3) reported that the presence of del
(17p) or TP53 mutations did not negatively affect clinical
outcomes among patients treated with Idela/R. The pre-
sent retrospective, multicenter study was undertaken with
the aim of testing whether SRSI was also useful for R/R
CLL patients treated with idelalisib–rituximab (Idela-R),
thus further refining the role of some prognostic factors in
predicting OS in a setting homogeneously treated for
patients.
Overall, 142 CLL patients present in the CLL databases
from 15 Italian centers (see Supplementary Appendix for
details), could be included in this analysis. The majority of
patients were Binet stages B and C (94.6%). The median
age was 75.1 years (range: 37.1–91) and 98 cases (69%)
were male. The median number of previous therapies was
3 (range: 1–9). Fifty-six patients discontinued Idela-R due
to toxicity, 20 for CLL progression, and 6 for Richter
transformation; 2 responding cases underwent an allo-
geneic stem cell transplantation. The baseline patients’
features are listed in Supplementary Table 2. After a
median follow-up of 1.6 years, 45 patients had died.
The relationship between the SRSI parameters and OS
was assessed. All three SRSI parameters were associated
with OS in univariate analysis and in a multiple Cox
regression analysis (Table 1). Thirty-six patients were clas-
sified at low risk, 76 at intermediate risk and 30 at high risk
according to the SRSI. The OS of the three patient groups
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was significantly different (Fig. 1), and an overlap among
curves was not observed across time. Low-risk patients had
a 2-year OS probability of 88.6% (HR= 1, reference cate-
gory), intermediate-risk patients of 69.6% (HR= 3.5, 95%
CI: 1.2–10.2, P= 0.022), and high-risk patients of 54.3%
(HR= 8.0, 95% CI: 2.7–23.7, P < 0.0001) (Fig. 1). The C
statistic was 0.66 (P < 0.001) for OS prediction (Fig. 1), a
figure reasonably close to the well-known critical cutoff of
0.7 useful to counsel an individual patient. Of note, no
statistically significant differences in terms of the number of
lines of therapy or of discontinuation of idelalisib for toxi-
city were observed in the three risk categories.
Recently, a retrospective pooled cohort study based on
an international collaboration collected information from
~2500 R/R CLL patients treated either with che-
moimmunotherapy or with new drugs (Ibrutinib, Idelali-
sib, or Venetoclax), and proposed a comprehensive risk
score for the OS prediction, based on four widely acces-
sible parameters: β2 M, anemia, LDH, and time from last
therapy, a.k.a. BALL score (Supplementary Table 2).2
According to the BALL score, 46 patients of the present
study were classified at low risk, 77 at intermediate risk
and 19 at high risk. Although significant differences in OS
were found between low-risk versus intermediate-risk
patients (P < 0.001), this stratification failed to detect
significant differences between intermediate-risk versus
high-risk cases (P= 0.057) (Supplementary Fig. 1). Since
the BALL score differs from SRSI for the presence of the
time from last therapy (≥24 versus <24 months) variable,
the prognostic power of this parameter was also evaluated
in our cohort. At univariate analysis, time from last
therapy was significantly associated with OS (HR= 2.27;
95% CI: 1.01–5.6; P= 0.049) (Table 1), but it lost its
prognostic significance when forced into a multivariate
model, together with the three parameters of the SRSI
score, which remained independently associated with OS
(Table 1).
The above differences were somewhat expected, given
that the BALL score was designed for R/R CLL patients
undergoing salvage treatment, using either biological
agents or chemoimmunotherapy, whereas the SRSI score
was specifically adapted for R/R patients undergoing BCR-
inhibitor treatment. Probably, the use of new drugs as
salvage therapy in this setting of patients can overcome
the negative prognostic impact of a short time from last
therapy (<24 months), as previously reported by our
group in the ibrutinib setting.1
Table 1 Univariate and multivariate analyses.







HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Hemoglobin
<110 g/L for women
<120 g/L for men
3.63 (1.87–7.05) <0.0001 2.36 (1.15–4.84) 0.02 2.19 (1.05–4.58) 0.036 2.37 (1.15–4.89) 0.019
β2 M ≥ 5 mg/L 3.98 (2.15–7.36) <0.0001 2.25 (1.13–4.48) 0.021 2.23 (1.12–4.46) 0.023 2.23 (1.12–4.46) 0.022
LDH > ULN 3.18 (1.73–5.87) <0.0001 2.29 (1.21–4.33) 0.011 2.21 (1.16–4.19) 0.016 2.03 (1.05–3.94) 0.035
Time from the last therapy <24 months 2.37 (1.01–5.6) 0.049 – – 1.51 (0.62–3.67) 0.365 – –
Age >65 years 0.66 (0.32–1.38) 0.274 – – – – – –
17p deletion positive 2.07 (1.14–3.78) 0.017 – – – – 1.59 (0.85–2.96) 0.15
IGHV unmutated 1.3 (0.93–1.74) 0.13 – – – – – –
HR hazard ratio, 95% CI 95% confidence interval, β2 M β2 microglobulin, ULN upper limit of normal.
Fig. 1 Overall survival of the entire population of 142 CLL
patients according to SRSI. (β2 M ≤ 5= 0 points; β2 M > 5= 1 point;
hemoglobin > 11 g/L for women and > 12 g/L for men= 0 points;
hemoglobin ≤ 11 g/L for women and ≤ 12 g/L for men= 2 points;
LDH ≤ UNL= 0 points; LDH > UNL= 2 points; total score 0= low risk;
score 1–3= intermediate risk; score 4–5= high risk).
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Finally, we evaluated the prognostic significance of two
biological parameters (i.e., IGHV mutational status and 17p
deletion) in our series. At univariate analysis, 17p deletion
(HR: 2.07; 95% CI: 1.14–3.78; P= 0.017) and not the IGHV
status (HR: 1.3; 95% CI: 0.93–1.74; P= 0.13) remained sig-
nificantly associated with survival (Table 1). Nonetheless, 17p
deletion failed to maintain its independent prognostic power
when added to LDH, β2-M values, and hemoglobin levels in
a multivariate model, while all three SRSI parameters
remained independently associated with survival (Table 1).
These data are in line with the exploratory analysis per-
formed in the Study 116 trial,3,4 indicating that the presence
of 17p deletion does not negatively affect the survival of R/R
CLL patients who are generally ineligible for standard che-
motherapy, but can be treated with Idela-R.3,4 At univariate
analysis, age (HR 0.66; 95% CI: 0.32–1.38; P= 0.274) did not
remain significantly associated with survival (Table 1).
Overall, the present data indicate that parameters rela-
ted to tumor burden (i.e., LDH and β2-M values) and to
bone marrow reserve (i.e., hemoglobin level) represent the
most important prognostic markers of survival in R/R
CLL patients receiving Idela-R. This is similar to what we
found for Ibrutinib, and suggests that these criteria may
be universally valuable for BCR inhibitors [survival risk
score for real-life R/R CLL patients treated with Ibrutinib
or with Idela-R (SRSII)]. Furthermore, SRSII is a simple
and parsimonious prognostic score, which is unlikely to
be affected by missing genetic data, when employed in
clinical practice. Nevertheless, in the absence of ad hoc
phase III randomized studies, the final choice of the most
appropriate BCR-inhibitor therapy is frequently dictated
by the presence of comorbidities or by the expected
toxicity drug profiles. In this context, the proposed SRSII
may represent an additional and easily applicable tool for
the prediction of OS in R/R CLL patients treated with
BCR inhibitors. However, in the current era of CLL
treatments that have relegated therapy with Idela-R to the
third or potentially fourth line of treatment, patients with
high-risk SRS score should be considered for a combi-
nation of new drugs, aimed at attaining undetectable
minimal residual disease and treatment-free remissions.
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